AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.

AbbVie presented 21 clinical presentations on blood cancer therapies at the European Hematology Association Congress, showcasing progress in its oncology portfolio which generated $6.7 billion in 2025 revenue. The company's diversified pipeline across immunology, oncology, and neuroscience is helping offset Humira's patent-driven decline and could support future dividend growth through expanded cash flow.